Terremoto Biosciences | ApexOnco - Clinical Trials news and analysis

x

“The insights provided by the analysts are great”

Director New Product Planning

Morphosys

Click here for more information

Data insights

20 August 2025

Astellas and Amgen join the pan-KRAS push

Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.

Subscribe to Terremoto Biosciences